Fig. 3
From: The longevity-promoting factor, TCER-1, widely represses stress resistance and innate immunity
TCER-1 links fertility and immunity. a TCER-1 does not inhibit immunity in post-reproductive adults. Schematic on left indicates age at which animals were transferred to PA14 plates. Mean survival (hours) upon PA14 exposure as L4 larvae: wild type (WT, black: 71.69), tcer-1 (blue: 79.97), reproductively active adults (blue): day 2: WT (40.89), tcer-1 (51.36), day 4: WT (31.41), tcer-1 (38.86) and at post-reproductive ages (pink): day 6: WT (24.82), tcer-1 (26.17) or day 9: WT (20.91), tcer-1 (19.6). b Fertility reduction caused by PA14. Egg-laying dynamics of late L4 larvae transferred to PA14 (purple, hashed) or control E. coli OP50 (black, solid). c, d Decline in egg laying caused by PA14 is limited by overexpressing TCER-1. Y-axes show percent rescue in egg laying 12 h after PA14 exposure by strains overexpressing TCER-1 (red bars, X-axes) in c individual somatic tissues or d under control of tcer-1 endogenous promoters, as compared to the 65% reduction in egg laying shown by WT (baseline). To control for differences in brood sizes, number of eggs laid by each strain on PA14 was normalized to its brood size on OP50. For assays (b–d), data combined from 2 to 10 biological replicates with 10−20 animals per strain per replicate. Statistical significance calculated using two-tailed, unpaired t test. Error bars denote standard error. e TCER-1 overexpression increases PA14 susceptibility. Survival (hours) of wild-type on control vector (WT/Ctrl, black; m = 57.47, n = 68/100) or tcer-1 RNAi (WT/tcer-1, blue, m = 108.46, n = 100/100) and endogenous promotor-driven TCER-1 transgenic strain (tcer-1 o/e) on control (tcer-1 oe/Ctrl, red; m = 43.46, n = 68/85) or tcer-1 RNAi (tcer-1 oe/tcer-1, purple, m = 57.96, n = 83/116). Survival data analyzed using Kaplan−Meier test. Asterisks indicate statistical significance <0.05 (*), and <0.0001 (****) and color denotes the strain of comparison. P values adjusted for multiplicity where applicable. Details of number of animals in panel a and data from additional trials in Supplementary Table 5
